The development of therapeutics and vaccines against COVID-19

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• The COVID-19 pandemic posed significant global health and economic challenges.
• Extensive clinical trials were conducted to identify effective treatments and preventive measures.
• Understanding therapeutic mechanisms and vaccine platforms is crucial for pandemic response.

Purpose of the Study:

• To review and analyze the efficacy of various therapeutic agents for COVID-19.
• To systematically evaluate mainstream COVID-19 vaccine platforms.
• To provide evidence-based guidelines for clinicians managing COVID-19.

Main Methods:

• Discussion of therapeutic agents including antivirals, tocilizumab, JAK inhibitors, neutralizing antibodies, and corticosteroids.
• Systematic analysis of four vaccine platforms: mRNA, viral vector, inactivated, and protein subunit vaccines.
• Evaluation of drug and vaccine effects through typical clinical trial data.

Main Results:

• Therapeutic agents demonstrate efficacy in managing COVID-19 progression.
• Vaccines, including mRNA and viral vector types, are effective in preventing SARS-CoV-2 infection.
• Emerging variants complicate the interpretation of clinical data for vaccines and antibody therapies.

Conclusions:

• Therapeutic agents are the primary choice for controlling COVID-19 disease progression in the post-epidemic era.
• Comprehensive assessment of vaccine effectiveness against diverse SARS-CoV-2 strains is necessary.
• Continued research is vital to address challenges posed by viral variants.